nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—kidney cancer—vaginal cancer	0.871	1	CtDrD
Sorafenib—CDKL3—female reproductive system—vaginal cancer	0.00226	0.0176	CbGeAlD
Sorafenib—CDKL2—female reproductive system—vaginal cancer	0.00207	0.0161	CbGeAlD
Sorafenib—MAPK15—female reproductive system—vaginal cancer	0.00186	0.0145	CbGeAlD
Sorafenib—CDK7—uterine cervix—vaginal cancer	0.00145	0.0113	CbGeAlD
Sorafenib—TAOK2—urethra—vaginal cancer	0.00132	0.0103	CbGeAlD
Sorafenib—ZAK—uterine cervix—vaginal cancer	0.00125	0.00975	CbGeAlD
Sorafenib—HIPK4—female reproductive system—vaginal cancer	0.00125	0.00975	CbGeAlD
Sorafenib—HIPK3—uterine cervix—vaginal cancer	0.00123	0.00954	CbGeAlD
Sorafenib—CDK7—uterus—vaginal cancer	0.00121	0.0094	CbGeAlD
Sorafenib—TIE1—epithelium—vaginal cancer	0.00116	0.00899	CbGeAlD
Sorafenib—ZAK—urethra—vaginal cancer	0.00115	0.00896	CbGeAlD
Sorafenib—TIE1—uterine cervix—vaginal cancer	0.00115	0.00892	CbGeAlD
Sorafenib—ZAK—endometrium—vaginal cancer	0.00113	0.00882	CbGeAlD
Sorafenib—HIPK3—endometrium—vaginal cancer	0.00111	0.00863	CbGeAlD
Sorafenib—MAPK11—female reproductive system—vaginal cancer	0.0011	0.00859	CbGeAlD
Sorafenib—ZAK—mammalian vulva—vaginal cancer	0.0011	0.00853	CbGeAlD
Sorafenib—CDK7—female reproductive system—vaginal cancer	0.00109	0.00845	CbGeAlD
Sorafenib—AURKC—female reproductive system—vaginal cancer	0.00107	0.00832	CbGeAlD
Sorafenib—TIE1—urethra—vaginal cancer	0.00105	0.0082	CbGeAlD
Sorafenib—ZAK—uterus—vaginal cancer	0.00104	0.00813	CbGeAlD
Sorafenib—MAPK11—female gonad—vaginal cancer	0.001	0.00782	CbGeAlD
Sorafenib—BRAF—endometrium—vaginal cancer	0.000994	0.00773	CbGeAlD
Sorafenib—EPHA6—female reproductive system—vaginal cancer	0.00099	0.00771	CbGeAlD
Sorafenib—CDK7—female gonad—vaginal cancer	0.000989	0.00769	CbGeAlD
Sorafenib—TAOK2—female gonad—vaginal cancer	0.000981	0.00763	CbGeAlD
Sorafenib—TAOK2—vagina—vaginal cancer	0.000975	0.00758	CbGeAlD
Sorafenib—EPHX2—urethra—vaginal cancer	0.000965	0.00751	CbGeAlD
Sorafenib—TIE1—uterus—vaginal cancer	0.000955	0.00743	CbGeAlD
Sorafenib—FLT4—epithelium—vaginal cancer	0.000955	0.00743	CbGeAlD
Sorafenib—ZAK—female reproductive system—vaginal cancer	0.000939	0.00731	CbGeAlD
Sorafenib—FGFR1—uterine cervix—vaginal cancer	0.000934	0.00727	CbGeAlD
Sorafenib—HIPK3—female reproductive system—vaginal cancer	0.000919	0.00715	CbGeAlD
Sorafenib—EPHX2—mammalian vulva—vaginal cancer	0.000919	0.00715	CbGeAlD
Sorafenib—BRAF—uterus—vaginal cancer	0.000916	0.00713	CbGeAlD
Sorafenib—MAP3K19—female reproductive system—vaginal cancer	0.0009	0.007	CbGeAlD
Sorafenib—MAP3K7—uterine cervix—vaginal cancer	0.000885	0.00688	CbGeAlD
Sorafenib—EPHX2—uterus—vaginal cancer	0.000875	0.00681	CbGeAlD
Sorafenib—MKNK2—epithelium—vaginal cancer	0.000865	0.00673	CbGeAlD
Sorafenib—TIE1—female reproductive system—vaginal cancer	0.000859	0.00668	CbGeAlD
Sorafenib—FGFR1—urethra—vaginal cancer	0.000859	0.00668	CbGeAlD
Sorafenib—MKNK2—uterine cervix—vaginal cancer	0.000857	0.00667	CbGeAlD
Sorafenib—ZAK—female gonad—vaginal cancer	0.000854	0.00665	CbGeAlD
Sorafenib—ZAK—vagina—vaginal cancer	0.000849	0.00661	CbGeAlD
Sorafenib—MKNK1—uterine cervix—vaginal cancer	0.000847	0.00659	CbGeAlD
Sorafenib—RET—epithelium—vaginal cancer	0.000843	0.00656	CbGeAlD
Sorafenib—HIPK3—female gonad—vaginal cancer	0.000836	0.00651	CbGeAlD
Sorafenib—HIPK3—vagina—vaginal cancer	0.000831	0.00647	CbGeAlD
Sorafenib—FGFR1—mammalian vulva—vaginal cancer	0.000817	0.00636	CbGeAlD
Sorafenib—MAP3K7—urethra—vaginal cancer	0.000813	0.00632	CbGeAlD
Sorafenib—MAP3K7—endometrium—vaginal cancer	0.0008	0.00622	CbGeAlD
Sorafenib—MKNK2—urethra—vaginal cancer	0.000788	0.00613	CbGeAlD
Sorafenib—TIE1—female gonad—vaginal cancer	0.000781	0.00608	CbGeAlD
Sorafenib—FLT3—female reproductive system—vaginal cancer	0.000781	0.00608	CbGeAlD
Sorafenib—FGFR1—uterus—vaginal cancer	0.000779	0.00606	CbGeAlD
Sorafenib—MKNK1—urethra—vaginal cancer	0.000778	0.00605	CbGeAlD
Sorafenib—MKNK2—endometrium—vaginal cancer	0.000775	0.00603	CbGeAlD
Sorafenib—RALBP1—uterine cervix—vaginal cancer	0.000774	0.00602	CbGeAlD
Sorafenib—MAP3K7—mammalian vulva—vaginal cancer	0.000774	0.00602	CbGeAlD
Sorafenib—MKNK1—endometrium—vaginal cancer	0.000766	0.00596	CbGeAlD
Sorafenib—MKNK2—mammalian vulva—vaginal cancer	0.00075	0.00584	CbGeAlD
Sorafenib—BRAF—female gonad—vaginal cancer	0.000749	0.00583	CbGeAlD
Sorafenib—BRAF—vagina—vaginal cancer	0.000745	0.00579	CbGeAlD
Sorafenib—FLT1—epithelium—vaginal cancer	0.000743	0.00578	CbGeAlD
Sorafenib—MKNK1—mammalian vulva—vaginal cancer	0.000741	0.00576	CbGeAlD
Sorafenib—RAF1—epithelium—vaginal cancer	0.000738	0.00575	CbGeAlD
Sorafenib—MAP3K7—uterus—vaginal cancer	0.000737	0.00574	CbGeAlD
Sorafenib—FLT1—uterine cervix—vaginal cancer	0.000736	0.00573	CbGeAlD
Sorafenib—RAF1—uterine cervix—vaginal cancer	0.000732	0.0057	CbGeAlD
Sorafenib—EPHB6—uterine cervix—vaginal cancer	0.000728	0.00566	CbGeAlD
Sorafenib—EPHX2—female gonad—vaginal cancer	0.000716	0.00557	CbGeAlD
Sorafenib—MKNK2—uterus—vaginal cancer	0.000715	0.00556	CbGeAlD
Sorafenib—EPHX2—vagina—vaginal cancer	0.000712	0.00554	CbGeAlD
Sorafenib—RALBP1—urethra—vaginal cancer	0.000712	0.00554	CbGeAlD
Sorafenib—FLT3—female gonad—vaginal cancer	0.000711	0.00553	CbGeAlD
Sorafenib—FLT4—female reproductive system—vaginal cancer	0.00071	0.00552	CbGeAlD
Sorafenib—RALBP1—endometrium—vaginal cancer	0.0007	0.00545	CbGeAlD
Sorafenib—STK10—uterine cervix—vaginal cancer	0.000697	0.00542	CbGeAlD
Sorafenib—RALBP1—mammalian vulva—vaginal cancer	0.000677	0.00527	CbGeAlD
Sorafenib—FLT1—urethra—vaginal cancer	0.000677	0.00527	CbGeAlD
Sorafenib—RAF1—urethra—vaginal cancer	0.000673	0.00523	CbGeAlD
Sorafenib—EPHB6—urethra—vaginal cancer	0.000669	0.0052	CbGeAlD
Sorafenib—FLT1—endometrium—vaginal cancer	0.000666	0.00518	CbGeAlD
Sorafenib—RAF1—endometrium—vaginal cancer	0.000662	0.00515	CbGeAlD
Sorafenib—EPHB6—endometrium—vaginal cancer	0.000658	0.00512	CbGeAlD
Sorafenib—FLT4—female gonad—vaginal cancer	0.000646	0.00502	CbGeAlD
Sorafenib—RALBP1—uterus—vaginal cancer	0.000645	0.00502	CbGeAlD
Sorafenib—FLT1—mammalian vulva—vaginal cancer	0.000644	0.00501	CbGeAlD
Sorafenib—MKNK2—female reproductive system—vaginal cancer	0.000642	0.005	CbGeAlD
Sorafenib—RAF1—mammalian vulva—vaginal cancer	0.000641	0.00498	CbGeAlD
Sorafenib—FGFR1—female gonad—vaginal cancer	0.000637	0.00496	CbGeAlD
Sorafenib—EPHB6—mammalian vulva—vaginal cancer	0.000637	0.00496	CbGeAlD
Sorafenib—MKNK1—female reproductive system—vaginal cancer	0.000634	0.00493	CbGeAlD
Sorafenib—FGFR1—vagina—vaginal cancer	0.000633	0.00493	CbGeAlD
Sorafenib—KDR—epithelium—vaginal cancer	0.000628	0.00489	CbGeAlD
Sorafenib—KDR—uterine cervix—vaginal cancer	0.000623	0.00484	CbGeAlD
Sorafenib—MAP2K5—uterine cervix—vaginal cancer	0.000623	0.00484	CbGeAlD
Sorafenib—FLT1—uterus—vaginal cancer	0.000614	0.00478	CbGeAlD
Sorafenib—RAF1—uterus—vaginal cancer	0.00061	0.00475	CbGeAlD
Sorafenib—STK10—mammalian vulva—vaginal cancer	0.00061	0.00475	CbGeAlD
Sorafenib—CSF1R—uterine cervix—vaginal cancer	0.000608	0.00473	CbGeAlD
Sorafenib—MAP3K7—female gonad—vaginal cancer	0.000603	0.00469	CbGeAlD
Sorafenib—MAP3K7—vagina—vaginal cancer	0.000599	0.00466	CbGeAlD
Sorafenib—MKNK2—female gonad—vaginal cancer	0.000584	0.00455	CbGeAlD
Sorafenib—STK10—uterus—vaginal cancer	0.000581	0.00452	CbGeAlD
Sorafenib—MKNK2—vagina—vaginal cancer	0.000581	0.00452	CbGeAlD
Sorafenib—RALBP1—female reproductive system—vaginal cancer	0.00058	0.00451	CbGeAlD
Sorafenib—MKNK1—female gonad—vaginal cancer	0.000577	0.00449	CbGeAlD
Sorafenib—PDGFRA—uterus—vaginal cancer	0.000575	0.00447	CbGeAlD
Sorafenib—MKNK1—vagina—vaginal cancer	0.000574	0.00446	CbGeAlD
Sorafenib—MAP2K5—urethra—vaginal cancer	0.000572	0.00445	CbGeAlD
Sorafenib—KDR—urethra—vaginal cancer	0.000572	0.00445	CbGeAlD
Sorafenib—KDR—endometrium—vaginal cancer	0.000563	0.00438	CbGeAlD
Sorafenib—MAP2K5—endometrium—vaginal cancer	0.000563	0.00438	CbGeAlD
Sorafenib—CSF1R—urethra—vaginal cancer	0.000558	0.00434	CbGeAlD
Sorafenib—KIT—epithelium—vaginal cancer	0.000556	0.00433	CbGeAlD
Sorafenib—FLT1—female reproductive system—vaginal cancer	0.000552	0.00429	CbGeAlD
Sorafenib—KIT—uterine cervix—vaginal cancer	0.000552	0.00429	CbGeAlD
Sorafenib—CSF1R—endometrium—vaginal cancer	0.000549	0.00428	CbGeAlD
Sorafenib—RAF1—female reproductive system—vaginal cancer	0.000549	0.00427	CbGeAlD
Sorafenib—KDR—mammalian vulva—vaginal cancer	0.000545	0.00424	CbGeAlD
Sorafenib—MAP2K5—mammalian vulva—vaginal cancer	0.000545	0.00424	CbGeAlD
Sorafenib—PDGFRB—epithelium—vaginal cancer	0.000543	0.00423	CbGeAlD
Sorafenib—PDGFRB—uterine cervix—vaginal cancer	0.000539	0.00419	CbGeAlD
Sorafenib—CSF1R—mammalian vulva—vaginal cancer	0.000532	0.00414	CbGeAlD
Sorafenib—RALBP1—female gonad—vaginal cancer	0.000528	0.00411	CbGeAlD
Sorafenib—RALBP1—vagina—vaginal cancer	0.000525	0.00408	CbGeAlD
Sorafenib—STK10—female reproductive system—vaginal cancer	0.000522	0.00406	CbGeAlD
Sorafenib—KDR—uterus—vaginal cancer	0.000519	0.00404	CbGeAlD
Sorafenib—PDGFRA—female reproductive system—vaginal cancer	0.000517	0.00402	CbGeAlD
Sorafenib—KIT—urethra—vaginal cancer	0.000507	0.00394	CbGeAlD
Sorafenib—CSF1R—uterus—vaginal cancer	0.000506	0.00394	CbGeAlD
Sorafenib—FLT1—female gonad—vaginal cancer	0.000502	0.00391	CbGeAlD
Sorafenib—RAF1—female gonad—vaginal cancer	0.000499	0.00388	CbGeAlD
Sorafenib—FLT1—vagina—vaginal cancer	0.000499	0.00388	CbGeAlD
Sorafenib—KIT—endometrium—vaginal cancer	0.000499	0.00388	CbGeAlD
Sorafenib—EPHB6—female gonad—vaginal cancer	0.000496	0.00386	CbGeAlD
Sorafenib—RAF1—vagina—vaginal cancer	0.000496	0.00386	CbGeAlD
Sorafenib—PDGFRB—urethra—vaginal cancer	0.000495	0.00385	CbGeAlD
Sorafenib—EPHB6—vagina—vaginal cancer	0.000493	0.00384	CbGeAlD
Sorafenib—PDGFRB—endometrium—vaginal cancer	0.000487	0.00379	CbGeAlD
Sorafenib—KIT—mammalian vulva—vaginal cancer	0.000483	0.00376	CbGeAlD
Sorafenib—STK10—female gonad—vaginal cancer	0.000475	0.0037	CbGeAlD
Sorafenib—STK10—vagina—vaginal cancer	0.000472	0.00368	CbGeAlD
Sorafenib—PDGFRB—mammalian vulva—vaginal cancer	0.000471	0.00367	CbGeAlD
Sorafenib—PDGFRA—female gonad—vaginal cancer	0.00047	0.00366	CbGeAlD
Sorafenib—PDGFRA—vagina—vaginal cancer	0.000468	0.00364	CbGeAlD
Sorafenib—KDR—female reproductive system—vaginal cancer	0.000466	0.00363	CbGeAlD
Sorafenib—MAP2K5—female reproductive system—vaginal cancer	0.000466	0.00363	CbGeAlD
Sorafenib—KIT—uterus—vaginal cancer	0.00046	0.00358	CbGeAlD
Sorafenib—CSF1R—female reproductive system—vaginal cancer	0.000455	0.00354	CbGeAlD
Sorafenib—PDGFRB—uterus—vaginal cancer	0.000449	0.00349	CbGeAlD
Sorafenib—HTR2B—uterine cervix—vaginal cancer	0.000427	0.00332	CbGeAlD
Sorafenib—MAP2K5—female gonad—vaginal cancer	0.000424	0.0033	CbGeAlD
Sorafenib—KDR—female gonad—vaginal cancer	0.000424	0.0033	CbGeAlD
Sorafenib—KDR—vagina—vaginal cancer	0.000422	0.00328	CbGeAlD
Sorafenib—MAP2K5—vagina—vaginal cancer	0.000422	0.00328	CbGeAlD
Sorafenib—CSF1R—female gonad—vaginal cancer	0.000414	0.00322	CbGeAlD
Sorafenib—KIT—female reproductive system—vaginal cancer	0.000413	0.00322	CbGeAlD
Sorafenib—CSF1R—vagina—vaginal cancer	0.000412	0.0032	CbGeAlD
Sorafenib—PDGFRB—female reproductive system—vaginal cancer	0.000404	0.00314	CbGeAlD
Sorafenib—HTR2B—endometrium—vaginal cancer	0.000386	0.003	CbGeAlD
Sorafenib—KIT—female gonad—vaginal cancer	0.000376	0.00293	CbGeAlD
Sorafenib—KIT—vagina—vaginal cancer	0.000374	0.00291	CbGeAlD
Sorafenib—PDGFRB—female gonad—vaginal cancer	0.000367	0.00286	CbGeAlD
Sorafenib—PDGFRB—vagina—vaginal cancer	0.000365	0.00284	CbGeAlD
Sorafenib—ABCC4—uterus—vaginal cancer	0.000358	0.00278	CbGeAlD
Sorafenib—HTR2B—uterus—vaginal cancer	0.000356	0.00277	CbGeAlD
Sorafenib—HTR2C—female reproductive system—vaginal cancer	0.00034	0.00265	CbGeAlD
Sorafenib—ABCC4—female reproductive system—vaginal cancer	0.000321	0.0025	CbGeAlD
Sorafenib—HTR2B—female reproductive system—vaginal cancer	0.00032	0.00249	CbGeAlD
Sorafenib—ABCC2—female reproductive system—vaginal cancer	0.000311	0.00242	CbGeAlD
Sorafenib—ABCG2—uterine cervix—vaginal cancer	0.000303	0.00236	CbGeAlD
Sorafenib—ABCC4—female gonad—vaginal cancer	0.000292	0.00228	CbGeAlD
Sorafenib—HTR2B—vagina—vaginal cancer	0.000289	0.00225	CbGeAlD
Sorafenib—CYP2C8—endometrium—vaginal cancer	0.000282	0.00219	CbGeAlD
Sorafenib—CYP3A5—uterine cervix—vaginal cancer	0.000281	0.00219	CbGeAlD
Sorafenib—ABCG2—urethra—vaginal cancer	0.000278	0.00217	CbGeAlD
Sorafenib—ABCG2—endometrium—vaginal cancer	0.000274	0.00213	CbGeAlD
Sorafenib—ABCG2—mammalian vulva—vaginal cancer	0.000265	0.00206	CbGeAlD
Sorafenib—ABCG2—uterus—vaginal cancer	0.000252	0.00196	CbGeAlD
Sorafenib—CYP2C19—vagina—vaginal cancer	0.000242	0.00188	CbGeAlD
Sorafenib—CYP2C8—female reproductive system—vaginal cancer	0.000233	0.00182	CbGeAlD
Sorafenib—CYP2C8—vagina—vaginal cancer	0.000211	0.00164	CbGeAlD
Sorafenib—CYP2B6—female reproductive system—vaginal cancer	0.000209	0.00163	CbGeAlD
Sorafenib—CYP2C9—female reproductive system—vaginal cancer	0.000207	0.00161	CbGeAlD
Sorafenib—ABCG2—female gonad—vaginal cancer	0.000206	0.00161	CbGeAlD
Sorafenib—ABCG2—vagina—vaginal cancer	0.000205	0.0016	CbGeAlD
Sorafenib—CYP3A5—female gonad—vaginal cancer	0.000192	0.00149	CbGeAlD
Sorafenib—CYP3A5—vagina—vaginal cancer	0.00019	0.00148	CbGeAlD
Sorafenib—CYP2B6—vagina—vaginal cancer	0.000189	0.00147	CbGeAlD
Sorafenib—CYP3A4—female reproductive system—vaginal cancer	0.000158	0.00123	CbGeAlD
Sorafenib—CYP2D6—female reproductive system—vaginal cancer	0.000156	0.00121	CbGeAlD
Sorafenib—ABCB1—epithelium—vaginal cancer	0.000151	0.00117	CbGeAlD
Sorafenib—ABCB1—uterine cervix—vaginal cancer	0.000149	0.00116	CbGeAlD
Sorafenib—CYP2D6—female gonad—vaginal cancer	0.000142	0.0011	CbGeAlD
Sorafenib—ABCB1—urethra—vaginal cancer	0.000137	0.00107	CbGeAlD
Sorafenib—ABCB1—endometrium—vaginal cancer	0.000135	0.00105	CbGeAlD
Sorafenib—ABCB1—mammalian vulva—vaginal cancer	0.000131	0.00102	CbGeAlD
Sorafenib—ABCB1—uterus—vaginal cancer	0.000124	0.000968	CbGeAlD
Sorafenib—ABCB1—female reproductive system—vaginal cancer	0.000112	0.000871	CbGeAlD
Sorafenib—ABCB1—female gonad—vaginal cancer	0.000102	0.000792	CbGeAlD
Sorafenib—ABCB1—vagina—vaginal cancer	0.000101	0.000787	CbGeAlD
